Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSP Gp96 vaccine - Cure and Sure Biotech

Drug Profile

HSP Gp96 vaccine - Cure and Sure Biotech

Alternative Names: Autologous Gp96 vaccine - Cure & Sure Biotech; Autologous heat shock protein Gp96 vaccine - Cure & Sure Biotech; Autologous tumour derived HSP Gp96 vaccine - Cure & Sure Biotech; HSP Gp96 vaccine - Cure & Sure Biotech; HSPPC-96 - Cure & Sure Biotech

Latest Information Update: 25 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cure&Sure Biotech
  • Developer Chinese Academy of Medical Sciences; Chinese PLA General Hospital; Cure&Sure Biotech
  • Class Cancer vaccines; Protein vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Gastric cancer; Liver cancer; Pancreatic cancer

Most Recent Events

  • 25 Jul 2022 Phase-II development in Glioblastoma (Adjuvant therapy) is ongoing in China (SC) (NCT03650257)
  • 19 Dec 2019 Cure and Sure Biotech plans a phase II/III trial for Liver cancer (SC) (NCT04206254)
  • 28 Mar 2019 No recent reports of development identified for phase-I development in Glioblastoma in China (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top